United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fulgent Genetics

Healthcare Services Group

Have $500? 3 Absurdly Cheap Healthcare Stocks Long-Term Investors Should Consider Buying Right Now

Pfizer Inc. (NYSE: PFE) CEO said the company is working on a specialized vaccine targeting the highly contagious delta variant of COVID-19. What Happened: “We are making a specialized vaccine for Delta.

Pfizer Working On Specialized Vaccine Targeting COVID-19 Delta Variant: CEO

The US Food and Drug Administration has approved the Pfizer Inc jab as its first COVID-19 vaccine, which had been used so far under the emergency use authorisation. President Joe Biden said it was a “key milestone” and encouraged people to get jabs.

Coronavirus: US issues full approval for Pfizer vaccine

Trillium Therapeutics

What do you do when you're brimming with billions of dollars in new vaccine revenue? You splurge, of course!

Pfizer To Buy Cancer Biotech Company Trillium For $2.3 Million

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Trillium Therapeutics Inc. (NasdaqCM: TRIL) to Pfizer Inc. (NYSE: PFE). Under the terms of the proposed transaction, shareholders of Trillium will receive only $18.50 in cash for each share of Trillium that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq

TRILLIUM THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Trillium Therapeutics Inc. - TRIL

Growth stocks and related exchange traded funds rallied Monday as investors shifted to a risk-on mood in response to the U.S. drug regulator granting full approval for Pfizer-BioNtech's Covid-19 vaccine. The U.S. Food and Drug Administration has fully approved the Pfizer Inc/BioNTech SE Covid-19 vaccine for people aged 16 and older, Reuters reports.

FDA's Full Pfizer Approval Fuels a Risk-On Rally

Led by shares of BioNTech (BNTX), which gained +9.6% on the day, the Nasdaq zoomed ahead to its single-best trading day since May 20th and finished at a brand new all-time high close.

Markets Surge on Pfizer Vax Approval

BioNTech SE

According to data published by the Health Ministry of Israel, the third dose of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX)'s COVID-19 vaccine has significantly improved protection from infection and serious illness in people aged 60 and older compared with those who received two shots. Full details of the study were not released.

Booster COVID Shot From Pfizer-BioNTech Significantly Cuts Infection Risk, Israel Study Shows

AMC Entertainment

Coinbase

FuelCell Energy

Canoo

Moderna

Plug Power

Romeo Power

Starbucks

Tesla

So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.

What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.

The shares of Pfizer Inc. (NYSE: PFE) increased by 2.48% today. This is why it happened.

Pfizer Shares Increased 2.48%: Why It Happened

A major regulatory approval sparked a rally in coronavirus vaccine stocks.

Why Pfizer, BioNTech, and Moderna Stocks Jumped Today

Alibaba

NVIDIA

Pfizer, Moderna, Nvidia and Alibaba were our top stock trades for Tuesday. Now, let's get a look at the charts as the market hits new highs.

4 Top Stock Trades for Tuesday: PFE, MRNA, NVDA, BABA

The Covid-19 vaccine produced by Pfizer Inc. (NYSE:PFE) in partnership with BioNTech (BNTX) has become the first to receive full approval from the U.S. Food and Drug Administration (FDA).

Pfizer's Big Vaccine Breakthrough Draws in Options Bulls

Pfizer Inc (NYSE: PFE) shares jumped more than 3.0% on Monday morning to a record $51 as its COVID-19 vaccine secured full FDA approval. The announcement comes on the same day when the U.S. pharmaceutical giant said it will buy Trillium Therapeutics Inc for $2.26 billion to expand its footprint in blood cancer therapies.

Here's why Mizuho's Divan still sees a 16% downside in Pfizer

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older. COMIRNATY is the first COVID-19 vaccine to be granted approval by the FDA. The vaccine has been available in the U.S. under Emergency Use Authorization (EUA) since December 11, 2020 (a

Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older

Pfizer Inc. (NYSE:PFE) shares were trading higher Monday after the company received FDA approval for its COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older.

What's Next For Pfizer Stock After FDA Approval Of COVID-19 Vaccine?

With the approval for polyarticular JIA and juvenile PsA, Pfizer's (PFE) Xeljanz is now approved for four indications in Europe.

Pfizer (PFE) Xeljanz Gets EC Nod for Kids Psoriatic Arthritis

The vaccine will be marketed under the brand name Comirnaty, and the FDA hopes the approval will nudge unvaccinated people to get vaccinated.

Pfizer and BioNTech surge after the FDA officially approves its COVID-19 vaccine

The milestone could encourage more people to get vaccinated.

Pfizer's COVID-19 vaccine wins full approval from the FDA

The U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer-BioNTech's COVID-19 vaccine, making it the first vaccine to achieve that status. The mRNA-based vaccine has been available since late last year through an Emergency Use Authorization (EUA), and will continue to be offered under that designation for those aged 12 to 15 […]

FDA fully approves Pfizer-BioNTech's COVID-19 vaccine

Pfizer soared 4%, while its German vaccine partner, BioNTech, climbed more than 10%.

Pfizer And Moderna Rally After FDA Grants Full Approval To Pfizer's Covid-19 Vaccine

Pfizer said it will pay $18.50 a share for the Cambridge, Massachusetts-based drug maker Trillium.

Pfizer to buy cancer drug maker Trillium for $2.3B

Louisiana-Pacific

Lowe's

Lululemon Athletica

Mettler-Toledo

Plexus

The Dow Jones gained 150 points, or nearly 0.5%, while the S&P 500 and Nasdaq rose about 0.5% each. Find opportunities in today's market with today's Top Buys from Q.ai's artificial intelligence.

Louisiana-Pacific Corp Ranked Among Today's Top Buys As FDA Grants Pfizer Vaccine Full Approval

Britain has ordered 35mln new doses of the Pfizer Covid-19 vaccine a day after a study in Israel showed a third or booster jab substantially reduces the risks to the elderly. The UK ordered 100mln doses of the vaccine when it first became available alongside 100mln of the Astra Zeneca alternative, but subsequent concerns about blood clots mean that those aged under 30 are now given either the Pfizer version or the closely related Moderna vaccine.

Britain orders more Pfizer Covid-19 jabs as booster programme nears

The company's vaccine received emergency use authorization in December. Since then, more than 200 million doses of the vaccine have been administered in the U.S. alone.

News for Pfizer Stock (PFE)